XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Financial Information with Respect to Company's Reportable Segments

Presented below is the financial information with respect to the Company’s reportable segments:

 

 

 

Three Months Ended June 30,

 

(in thousands)

 

2019

 

 

2018

 

Revenue:

 

 

 

 

 

 

 

 

Therapeutics

 

$

4,819

 

 

$

1,447

 

Food

 

 

570

 

 

 

427

 

Total segment revenue

 

 

5,389

 

 

 

1,874

 

Segment operational cash expenditures:

 

 

 

 

 

 

 

 

Therapeutics

 

$

14,872

 

 

$

4,926

 

Food

 

 

2,077

 

 

 

674

 

Total segment operational cash expenditures

 

 

16,949

 

 

 

5,600

 

Allocation of centralized research and development operational

   cash expenditures:

 

 

 

 

 

 

 

 

Therapeutics

 

$

3,118

 

 

$

1,905

 

Food

 

 

 

 

 

816

 

Total allocation of centralized research and development

   operational cash expenditures

 

 

3,118

 

 

 

2,721

 

Segment operating loss:

 

 

 

 

 

 

 

 

Therapeutics

 

$

(13,171

)

 

$

(5,384

)

Food

 

 

(1,507

)

 

$

(1,063

)

Total segment operating loss

 

 

(14,678

)

 

 

(6,447

)

Adjustments to reconcile segment operating loss to consolidated

   loss from operations:

 

 

 

 

 

 

 

 

Corporate general and administrative cash expenditures

 

$

(11,123

)

 

$

(2,118

)

Interest income received

 

 

(1,485

)

 

 

(299

)

Depreciation and amortization

 

 

(1,168

)

 

 

(512

)

Share-based compensation

 

 

(2,279

)

 

 

(255

)

Loss on disposal of assets

 

 

(22

)

 

 

(3

)

Changes in prepaids, accounts payable and accrued expenses

 

 

6,884

 

 

 

(2,491

)

Total consolidated loss from operations

 

$

(23,871

)

 

$

(12,125

)

 

 

 

Six Months Ended June 30,

 

(in thousands)

 

2019

 

 

2018

 

Revenue:

 

 

 

 

 

 

 

 

Therapeutics

 

$

9,638

 

 

$

2,894

 

Food

 

 

1,213

 

 

 

508

 

Total segment revenue

 

 

10,851

 

 

 

3,402

 

Segment operational cash expenditures:

 

 

 

 

 

 

 

 

Therapeutics

 

$

27,782

 

 

$

14,176

 

Food

 

 

4,184

 

 

 

1,733

 

Total segment operational cash expenditures

 

 

31,966

 

 

 

15,909

 

Allocation of centralized research and development operational

   cash expenditures:

 

 

 

 

 

 

 

 

Therapeutics

 

$

6,871

 

 

$

3,942

 

Food

 

 

 

 

 

1,233

 

Total allocation of centralized research and development

   operational cash expenditures

 

 

6,871

 

 

 

5,175

 

Segment operating loss:

 

 

 

 

 

 

 

 

Therapeutics

 

$

(25,015

)

 

$

(15,224

)

Food

 

 

(2,971

)

 

 

(2,458

)

Total segment operating loss

 

 

(27,986

)

 

 

(17,682

)

Adjustments to reconcile segment operating loss to consolidated

   loss from operations:

 

 

 

 

 

 

 

 

Corporate general and administrative cash expenditures

 

$

(18,145

)

 

$

(4,677

)

Interest income received

 

 

(2,086

)

 

 

(522

)

Depreciation and amortization

 

 

(2,107

)

 

 

(970

)

Share-based compensation

 

 

(3,828

)

 

 

(405

)

Loss on disposal of assets

 

 

(22

)

 

 

(10

)

Changes in prepaids, accounts payable and accrued expenses

 

 

10,809

 

 

 

2,906

 

Total consolidated loss from operations

 

$

(43,365

)

 

$

(21,360

)